OmniAb to Report Third Quarter 2024 Financial Results on November 12
OmniAb, Inc. (NASDAQ: OABI) has announced that it will report its financial results for the third quarter of 2024 on Tuesday, November 12, 2024. The company will release the results after the close of U.S. financial markets and will host a conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) on the same day.
Interested parties can access the conference call via phone using the following numbers:
- U.S.: (800) 549 8228
- International: (289) 819 1520
- Conference ID: 94399
Additionally, a live webcast of the call, including slides, will be available. A replay of the webcast will also be accessible after the call.
OmniAb, Inc. (NASDAQ: OABI) ha annunciato che riporterà i suoi risultati finanziari per il terzo trimestre del 2024 martedì 12 novembre 2024. La società renderà noti i risultati dopo la chiusura dei mercati finanziari statunitensi e ospiterà una chiamata in conferenza alle 16:30 Ora dell'Est (13:30 ora del Pacifico) lo stesso giorno.
Le parti interessate possono accedere alla chiamata in conferenza telefonando ai seguenti numeri:
- U.S.: (800) 549 8228
- Internazionale: (289) 819 1520
- ID conferenza: 94399
Inoltre, sarà disponibile un webcast in diretta della chiamata, inclusi i diapositive. Una registrazione del webcast sarà accessibile anche dopo la chiamata.
OmniAb, Inc. (NASDAQ: OABI) ha anunciado que reportará sus resultados financieros para el tercer trimestre de 2024 el martes 12 de noviembre de 2024. La compañía publicará los resultados después del cierre de los mercados financieros de EE. UU. y realizará una llamada en conferencia a las 4:30 p.m. hora del Este (1:30 p.m. hora del Pacífico) el mismo día.
Las partes interesadas pueden acceder a la llamada en conferencia por teléfono utilizando los siguientes números:
- EE. UU.: (800) 549 8228
- Internacional: (289) 819 1520
- ID de conferencia: 94399
Además, estará disponible un webcast en vivo de la llamada, incluidos los diapositivas. También se podrá acceder a una grabación del webcast después de la llamada.
OmniAb, Inc. (NASDAQ: OABI)는 2024년 3분기 재무 실적 발표를 2024년 11월 12일 화요일에 할 것이라고 발표했습니다. 이 회사는 미국 금융 시장이 닫힌 후 결과를 발표하며, 같은 날 동부 표준시 기준 오후 4시 30분 (태평양 표준시 기준 오후 1시 30분)에 컨퍼런스 콜을 진행할 것입니다.
관심 있는 당사자는 다음 번호로 전화를 통해 컨퍼런스 콜에 접속할 수 있습니다:
- 미국: (800) 549 8228
- 국제: (289) 819 1520
- 컨퍼런스 ID: 94399
또한, 실시간 웹캐스트가 제공되며 슬라이드도 포함됩니다. 콜 이후에는 웹캐스트 재생도 이용할 수 있습니다.
OmniAb, Inc. (NASDAQ: OABI) a annoncé qu'elle publiera ses résultats financiers pour le troisième trimestre 2024 le mardi 12 novembre 2024. La société publiera les résultats après la fermeture des marchés financiers américains et animera une conférence téléphonique à 16h30 heure de l'Est (13h30 heure du Pacifique) le même jour.
Les parties intéressées peuvent accéder à la conférence téléphonique par téléphone en utilisant les numéros suivants :
- États-Unis : (800) 549 8228
- International : (289) 819 1520
- ID de la conférence : 94399
De plus, un webinaire en direct de l'appel, incluant les diapositives, sera disponible. Une rediffusion du webinaire sera également accessible après l'appel.
OmniAb, Inc. (NASDAQ: OABI) hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 am Dienstag, den 12. November 2024, bekannt geben wird. Das Unternehmen wird die Ergebnisse nach dem Schließen der US-Finanzmärkte veröffentlichen und am selben Tag um 16:30 Uhr Eastern Time (13:30 Uhr Pacific Time) eine Konferenzschalte abhalten.
Interessierte Parteien können über die folgenden Nummern auf die Konferenzschalte zugreifen:
- USA: (800) 549 8228
- International: (289) 819 1520
- Konferenz-ID: 94399
Zusätzlich wird ein Live-Webcast der Sitzung, einschließlich Folien, verfügbar sein. Ein Replay des Webcasts wird auch nach dem Anruf zugänglich sein.
- None.
- None.
Conference Call and Webcast Information
What: |
|
OmniAb conference call to discuss third quarter financial results and business updates |
|
|
|
Date: |
|
Tuesday, November 12, 2024 |
|
|
|
Time: |
|
4:30 p.m. Eastern time (1:30 p.m. Pacific time) |
|
|
|
Phone: |
|
|
|
|
International (289) 819 1520 |
|
|
Conference ID is 94399 |
|
|
|
Webcast: |
|
Live and replay webcast of the call with slides will be available here. |
About OmniAb®
OmniAb licenses cutting edge discovery research technology to the pharmaceutical and biotech industry to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligence™ (BI), which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics.
Our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® have been genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic® and OmniClic® are fixed or common light-chain rats and chickens, respectively, designed to facilitate the discovery of bispecific antibodies. OmniTaur™ provides cow-inspired antibodies with unique structural characteristics for challenging targets. OmnidAb™, is an in vivo platform for the discovery of single domain antibodies based upon a human VH scaffold that affinity matures in a chicken host environment to provide a functionally diverse immune repertoire unavailable from mammalian systems. Our proprietary technologies are joined with and leverage OmniDeep™, which is a suite of in silico, AI and machine learning tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many important and emerging target classes.
OmniAb technologies can be leveraged for the discovery of a variety of next-generation antibody-based therapeutic modalities, including bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, targeted radiotherapeutics, and many others.
For more information, please visit www.omniab.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241022649071/en/
OmniAb, Inc.
Neha Singh, Ph.D.
investors@OmniAb.com
X @OmniAbTech
(510) 768-7760
Source: OmniAb, Inc.
FAQ
When will OmniAb (OABI) report its Q3 2024 financial results?
What time is OmniAb's (OABI) Q3 2024 earnings conference call?
How can I access OmniAb's (OABI) Q3 2024 earnings call?
Will there be a replay of OmniAb's (OABI) Q3 2024 earnings call?
